1. Introduction

Legal tracking of biological material origin refers to the legal and regulatory mechanisms used to identify, document, verify, and trace the origin and subsequent movement of biological materials throughout their lifecycle—from collection and acquisition to research, processing, commercialisation, transfer, and disposal.

Biological materials may include:

Human blood, tissues, cells, DNA, and other biological specimens.

Plant varieties, seeds, medicinal herbs, and agricultural genetic resources.

Microorganisms, bacteria, fungi, viruses, and other biological agents.

Animal tissues, genetic samples, and reproductive material.

Laboratory-developed cell lines, genetically modified organisms, and synthetic biological materials derived from natural resources.

The central legal question is: Can an institution establish where a biological material came from, whether it was lawfully obtained, who was authorised to use it, and whether all applicable consent, safety, ownership, and benefit-sharing obligations have been fulfilled?

Origin tracking is important for preventing biopiracy, protecting human rights, preserving biodiversity, ensuring scientific reproducibility, enforcing intellectual property rights, and establishing evidentiary accountability.

In India, this subject intersects with the Patents Act, 1970, the Biological Diversity Act, 2002, applicable rules and regulations, human biomedical research requirements, environmental legislation, and international instruments such as the Convention on Biological Diversity and the Nagoya Protocol. The precise rules depend on the type of material and the activity involved.

2. Meaning and principal legal dimensions

An important distinction is that origin, source, ownership, and lawful possession are not interchangeable concepts. A laboratory may lawfully possess a sample without owning all rights associated with it. Likewise, identifying a sample's country of origin does not by itself establish that the sample was lawfully collected.

3. Legal framework in India

A. Patents Act, 1970

The Patents Act is one of the most direct legal mechanisms for tracking biological material used in inventions.

Section 10(4)(d) addresses situations in which an invention involves biological material that cannot be adequately described in the patent specification and is not publicly available. Subject to the statutory conditions, the material must be deposited with a recognised International Depository Authority under the Budapest Treaty.

The relevant provisions include:

Section 10(4)(d): Deposit of certain biological materials and disclosure of their identifying details.

Section 10(4)(ii)(D): Disclosure of the source and geographical origin of biological material used in an invention.

Section 25(1)(j) and Section 25(2)(j): Pre-grant and post-grant opposition grounds concerning failure to disclose or wrongful disclosure of the source or geographical origin of biological material.

Section 64(1)(p): Revocation of a patent on the specified ground of non-disclosure or wrongful disclosure of source or geographical origin.

These provisions are important because a patent applicant should not be able to obscure the biological origins of material relevant to an invention. Nevertheless, patent disclosure does not, by itself, prove that collection or commercial use complied with every other applicable law.

Indian Kanoon+1

B. Biological Diversity Act, 2002

India's biological-resource framework regulates access to biological resources and associated traditional knowledge, including applicable approval, notification, and benefit-sharing requirements.

Its institutional structure includes:

National Biodiversity Authority (NBA).

State Biodiversity Boards (SBBs) and relevant Union Territory authorities.

Biodiversity Management Committees (BMCs) at the local level.

Sections 3, 4, 6, 7 and 21 are particularly relevant, although their application depends on the actor, activity, resource, and applicable exemptions.

India's compliance framework has evolved through the 2023 amendments, the Biological Diversity Rules, 2024, and subsequent amendments to those Rules. The National Biodiversity Authority identifies the 2024 Rules as having superseded the 2004 Rules, with a further amendment notified in 2025. Therefore, compliance assessments should use the rules and regulations applicable to the relevant transaction and date.

National Biodiversity Authority+2

C. Convention on Biological Diversity and Nagoya Protocol

The international framework provides the basis for tracking genetic resources and ensuring that benefits from their utilisation are shared fairly.

The Convention on Biological Diversity (CBD) recognises national sovereignty over genetic resources, subject to applicable international and domestic law. The Nagoya Protocol develops the access-and-benefit-sharing framework.

Relevant principles include:

Access to genetic resources under the applicable national access regime.

Prior informed consent where required.

Mutually agreed terms governing access and benefit-sharing where applicable.

Documentation of lawful access and utilisation.

Cooperation between provider and user countries.

Article 17 of the Nagoya Protocol establishes a monitoring framework involving information checkpoints and internationally recognised certificates of compliance. These mechanisms can help establish whether access complied with the provider country's requirements.

However, the Protocol does not impose a universal requirement that every patent application worldwide disclose biological-resource origin. The precise disclosure duties depend on national law.

WIPO+1

4. Case laws and judicial principles

The following cases illustrate how courts and tribunals have addressed biological-resource access, genetic material, patents, and benefit sharing. Some concern the broader legal framework rather than a standalone right to track provenance.

Case 1: Divya Pharmacy v. Union of India (2018)

Uttarakhand High Court · Biological-resource access and benefit sharing

Legal issue: Whether Indian entities using biological resources for commercial purposes could be subject to benefit-sharing obligations under the Biological Diversity Act.

Principle: The case is an important authority on the application of the Act's access-and-benefit-sharing framework to Indian commercial entities. Section 7's prior-intimation regime does not automatically eliminate the possibility of benefit-sharing obligations.

Relevance to origin tracking: A commercial user should be able to identify the biological resources it acquires, the relevant suppliers or sources, and the quantities and uses associated with them. Such records help determine whether the correct regulatory process was followed and whether benefit-sharing obligations arise.

Legal significance: Resource traceability supports the enforcement of biodiversity law and helps connect commercial activity with the biological resources from which economic value is derived.

IndiaCode

Case 2: Nuziveedu Seeds Ltd. v. Monsanto Technology LLC (2018)

Delhi High Court · FAO (OS) (COMM) 86/2017 and connected appeal · Judgment dated 11 April 2018

Background: The dispute involved Monsanto's Bt cotton technology, including patent claims relating to a genetic sequence and methods for introducing it into plant cells.

Legal issues: The proceedings concerned patentability, genetically modified plant technology, licensing arrangements, and the statutory treatment of biological inventions.

The judgment discusses the Patents Act's requirements concerning biological-material deposits and disclosure of source and geographical origin.

Indian Kanoon+1

Relevance to origin tracking: The case demonstrates why biological invention records should distinguish between:

The original biological source.

The genetic sequence derived from that source.

A synthesised or modified sequence.

The process used to introduce the sequence into another organism.

The resulting invention and the rights claimed over it.

Legal significance: A record showing that a sequence was used in a plant-engineering process is not necessarily sufficient to establish the lawful origin of the underlying biological material. Provenance and patentability are related but separate questions.

Case 3: Dabur India Limited v. National Biodiversity Authority (2023)

National Green Tribunal, Southern Zone · Appeal No. 54 of 2022 (SZ) · Decision dated 20 December 2023

Background: The dispute concerned Dabur's use of multiple herbs in Ayurvedic medicines and healthcare products and the calculation of access-and-benefit-sharing obligations.

The tribunal examined the distinction between calculating benefits by reference to the value of biological resources and calculating them by reference to the value of finished products.

Indian Kanoon+1

Relevance to origin tracking: This case illustrates the commercial importance of maintaining records that connect raw biological resources to finished products.

Useful records may include:

Supplier and purchase records for herbs.

Species and quantity information.

The intended commercial use of each resource.

Manufacturing and product-batch records.

Regulatory filings and benefit-sharing agreements.

Legal significance: In a supply chain involving numerous biological ingredients, traceability supports the determination of which resources were used, how they were used, and which benefit-sharing methodology applies.

The case should not be read as establishing that every biological purchase automatically attracts identical approval or payment requirements. Those questions depend on the applicable legislation, exemptions, and regulatory provisions.

Case 4: Forschunge v. The Controller General of Patents (2026)

Indian patent proceedings · Judgment dated 17 June 2026

The reported decision addresses disclosure of biological material's source and geographical origin under Section 10(4)(d) of the Patents Act. The judgment emphasises the significance of biological-material disclosure for patent sufficiency and preventing biopiracy.

Indian Kanoon

Relevance to origin tracking: Where biological material is used in an invention, an applicant must examine whether the statutory disclosure and deposit requirements apply and ensure that the patent specification contains the required information.

Important qualification: The decision should be consulted in its full text before relying on its precise holding, procedural history, or any subsequent appellate developments.

Case 5: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120

Background: John Moore's cells were used in research that led to the development of a commercially valuable cell line. He alleged, among other things, that researchers had failed to disclose their financial interests and the potential commercial value of the research.

Judgment: The court rejected Moore's conversion claim based on a continuing ownership interest in the excised cells, but recognised that informed-consent and fiduciary-duty issues could arise from the alleged failure to disclose relevant interests.

Relevance to origin tracking: This case illustrates why provenance records alone are insufficient. A laboratory might know exactly where cells came from but still face legal issues if consent, disclosure of conflicts of interest, or research authorisation was inadequate.

Legal significance: The case is frequently discussed in debates about biological samples, commercial research, donor rights, and the distinction between physical possession and legal ownership. Its specific property-law holding is jurisdiction-dependent and should not be assumed to apply in India.

PubMed Central (PMC)

Case 6: Turmeric Patent Dispute — University of Mississippi Medical Center (1997–1998)

United States Patent and Trademark Office · Re-examination of US Patent No. 5,401,504

Background: A United States patent had been granted for the use of turmeric in wound healing. India's Council of Scientific and Industrial Research (CSIR) challenged the patent by submitting evidence of earlier traditional knowledge and published literature.

Outcome: The patent claims were rejected during re-examination because the claimed subject matter lacked novelty in light of the prior art.

Relevance to origin tracking: The dispute illustrates the importance of documenting where knowledge and biological-resource information originated, including whether an asserted invention relies on traditional uses already known to communities.

Legal significance: Historical records, scientific publications, traditional-knowledge databases, and reliable source documentation can help prevent the misappropriation of existing knowledge through inappropriate patent claims.

The dispute was principally about patent novelty, not a judicial determination of ownership over every turmeric resource or a general ruling on biological-material chain of custody.

5. What constitutes a legally defensible traceability system?

A robust system should document each stage of a material's lifecycle.

Stage 1 — Origin identification

Record the species, sample identifier, collection location where appropriate, collection date, source institution, and relevant taxonomic or genetic identifiers.

Stage 2 — Legal acquisition

Retain permits, applicable prior informed consent, collection permissions, access approvals, supplier declarations, material-transfer agreements, and benefit-sharing terms.

Stage 3 — Chain of custody

Record each transfer, recipient, quantity, storage location, processing event, and sample transformation. Link derivative samples to their parent material.

Stage 4 — Research and development

Document experiments, genetic modifications, derived cell lines, sequencing data, and any changes in intended use that may trigger new legal requirements.

Stage 5 — Commercialisation and audit

Link material to product batches, applicable patent disclosures, export records, regulatory submissions, benefit-sharing payments, and final disposal or retention.

These stages form a recommended compliance model, not a universal statutory checklist applicable to every biological sample.

6. Evidentiary standards and digital tracking

Legal tracking depends not merely on collecting information but on establishing its reliability.

Common forms of evidence include:

Collection permits, invoices, and signed transfer agreements.

Laboratory notebooks, sample accession registers, and inventory records.

DNA barcoding, sequencing, or other scientific identification evidence.

Geographical records and collection metadata.

Digital timestamps, access logs, and version-controlled records.

Patent specifications, repository deposit certificates, and regulatory filings.

Role of digital technologies

The central evidentiary principle is that technical traceability supports legal proof but does not replace legal authorisation.

7. International comparison

Legal duties differ across jurisdictions, particularly where genetic resources cross borders.

For cross-border research, a lawful transfer in the country of collection does not automatically establish lawful use in the destination country. Both jurisdictions' applicable requirements should be assessed.

8. Legal consequences of defective origin tracking

Failure to establish biological material's origin can lead to several different consequences, depending on the governing law and the nature of the breach.

Patent consequences: Opposition, rejection, or revocation where the applicable statutory grounds are established.

Biodiversity-law consequences: Regulatory proceedings, benefit-sharing determinations, or penalties where authorised by law.

Contractual consequences: Breach of material-transfer agreements, research licences, or access-and-benefit-sharing terms.

Research consequences: Institutional investigations, suspension of research, or withdrawal of improperly obtained materials.

Privacy and consent consequences: Liability or regulatory action where human specimens or genetic information were collected or used unlawfully.

Evidentiary consequences: Difficulty proving lawful acquisition, sample identity, or the integrity of scientific results.

A missing record does not automatically establish illegal acquisition. Conversely, possession of a complete set of records does not conclusively prove compliance if the underlying information is false or the required authorisation was never obtained.

9. Practical compliance checklist for India

An organisation handling biological material should ask:

Has the biological material been identified and its immediate source recorded?

Is the geographical origin known, or is the uncertainty expressly documented?

Were the material and associated traditional knowledge lawfully accessed?

Are applicable NBA, SBB, environmental, export, and institutional requirements satisfied?

Are human-sample consent, confidentiality, and research-ethics requirements addressed where relevant?

Are transfers and derivative samples linked to the original material?

Have the relevant patent deposit and source-disclosure requirements been met?

Have applicable benefit-sharing obligations and agreements been documented?

Can the organisation produce reliable records during an audit or legal proceeding?

10. Conclusion

Legal tracking of biological material origin is a multidisciplinary compliance mechanism linking biological identity, geographical provenance, lawful acquisition, custody, research, intellectual property, and benefit sharing.

Indian law provides particularly significant mechanisms through Section 10(4) of the Patents Act and the access-and-benefit-sharing framework under the Biological Diversity Act. Cases such as Divya Pharmacy, Nuziveedu Seeds, and Dabur India illustrate how these obligations intersect with commercial use, biotechnology, and biodiversity governance.

The overarching legal principle is that the right to use, research, transfer, or commercialise biological material must be assessed separately from the ability to identify or possess it. Effective tracking makes those legal relationships transparent, verifiable, and enforceable.

Disclaimer: This is a general legal research overview, not legal advice. For a live matter, the exact statutory text, applicable amendments, regulatory notifications, and subsequent judicial developments should be verified before taking action.